Malaria: Clinical Trials

264 trials for Malaria, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

264 completed. 264 Phase 1, 58 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1264Completed 264
Phase 258Completed 58

Follow Malaria: new trials by email Literature Review of Malaria trials Research Report on Malaria

Trials (filtered) newest first · largest first

All 264 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 Years
Midazolam (MDZ), GSK3772701 - Malaria, Falciparum
Phase 1CompletedGlaxoSmithKline202026-06-262026-09-30
Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso
SUM-101 - Malaria,Falciparum
Phase 1CompletedEuropean Vaccine Initiative392025-08-012026-09-11
First-in-Human PfSPZ-LARC2 Vaccination/CHMI
PfSPZ Vaccine, PfSPZ (7G8) Challenge, Sodium Chloride, 0.9% - Malaria
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)222025-07-232026-08-17
Controlled Human Malaria Infection by Mosquito Bites Using a Local Strain of Plasmodium Falciparum
Controlled Human Malaria Infection - Malaria (Plasmodium Falciparum)
Phase 1CompletedCentre de Recherche Médicale de Lambaréné202025-07-182026-09-11
Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population
MAM01 300 mg SC, MAM01 300 mg IM, MAM01 2000 mg IV - Healthy Volunteers
Phase 1CompletedGates Medical Research Institute1252025-03-282026-06-03
Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
PfSPZ-LARC2 Vaccine, Normal Saline (Placebo) - Malaria Falciparum, Malaria Infection
Phase 1CompletedSanaria Inc.752025-03-042026-04-16
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants
MMV371 LAI, Placebo for MMV371 - Malaria,Falciparum
Phase 1CompletedMedicines for Malaria Venture322024-08-272026-05-05
L9LS MAb in Malian Infants
L9LS, Placebo, R21/Matrix-MTM - Malaria
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)3272024-08-192026-10-01
Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali
TB31F, Normal saline - Malaria,Falciparum
Phase 1 / Phase 2CompletedRadboud University Medical Center1672024-07-122026-01-22
A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)
Plasmodium falciparum, MK-7602, Artemether/lumefantrine - Malaria
Phase 1CompletedMerck Sharp & Dohme LLC162024-04-182025-01-13
A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™
R21/Matrix M™ (Group 1), R21/Matrix M™ (Group 2), R21/Matrix M™ (Group 3) - Malaria,Falciparum
Phase 1CompletedUniversity of Oxford362024-03-252026-10-21
A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants
GSK4024484C, Placebo - Malaria, Falciparum
Phase 1CompletedGlaxoSmithKline1232023-12-112026-07-08
A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
BNT165c, BNT165d, Placebo - Malaria
Phase 1 / Phase 2CompletedBioNTech SE1632023-11-132026-08-28
Pan-Malaria Transmission-Blocking Vaccine AnAPN1
Vaccine AnAPN1 - Malaria
Phase 1CompletedCentre de Recherche Médicale de Lambaréné332023-09-112025-05-02
Assessment of the Malaria Vaccine Candidate SumayaVac-1 in Healthy Adults Aged 18-45 Years Living in a Malaria Endemic Country
SumayaVac-1(SUM-101), Verorab - Malaria
Phase 1CompletedSwiss Tropical & Public Health Institute402023-08-252024-04-15
A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines
RH5.1 and/or RH5.2-VLP with Matrix-M - Malaria, Malaria,Falciparum
Phase 1 / Phase 2CompletedUniversity of Oxford412023-08-182026-07-20
Piperaquine Granule Formulation Relative Bioavailability and Food Effect Study in Healthy Volunteers.
Piperaquine Tetraphosphate uncoated tablets, Piperaquine Tetraphosphate dispersible granules - Malaria
Phase 1CompletedMedicines for Malaria Venture602023-08-142025-03-18
Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults
MAM01 1.5 mg/kg, Placebo, MAM01 5 mg/kg - Malaria
Phase 1CompletedGates Medical Research Institute632023-08-142026-06-12
Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults
Pvs230D1-EPA/Matrix-M - Malaria
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)1052023-08-042025-12-01
Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum
MMV367 3mg, P. falciparum IBSM infection, MMV367 5mg - Infections, Vector Borne Diseases
Phase 1CompletedMedicines for Malaria Venture122023-08-012025-12-10

Showing 20 of 264. Sign in to see all of them.

Narrower conditions

Malaria, Falciparum (103)  ·  Malaria, Vivax (15)  ·  Parasitemia (8)  ·  Infections (6)  ·  Parasitic Diseases (4)  ·  Burkitt Lymphoma (3)  ·  Malaria, Cerebral (3)  ·  Protozoan Infections (3)  ·  Adenoviridae Infections (2)  ·  Glucosephosphate Dehydrogenase Deficiency (2)  ·  HIV Infections (2)  ·  HIV Seropositivity (2)  ·  Hemolysis (2)  ·  Vector Borne Diseases (2)

Broader conditions

Mosquito-Borne Diseases (264)  ·  Vector Borne Diseases (262)  ·  Protozoan Infections (261)  ·  Parasitic Diseases (260)  ·  Infections (258)  ·  Pathological Conditions, Signs and Symptoms (11)  ·  Pathologic Processes (9)  ·  Virus Diseases (9)  ·  Sepsis (8)  ·  Hemic and Lymphatic Diseases (7)  ·  Immune System Diseases (7)  ·  Inflammation (7)  ·  Systemic Inflammatory Response Syndrome (7)  ·  DNA Virus Infections (5)

Interventions

Saline Solution (15)  ·  Artemether, Lumefantrine Drug Combination (12)  ·  Primaquine (11)  ·  Chloroquine (9)  ·  Matrix-M (7)  ·  Artesunate (6)  ·  Rabies Vaccines (6)  ·  Aluminum Hydroxide (5)  ·  Lumefantrine (5)  ·  ProMune (5)  ·  Sodium Chloride (5)  ·  artefenomel (5)  ·  atovaquone, proguanil drug combination (5)  ·  fanasil, pyrimethamine drug combination (5)  ·  tafenoquine (5)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (47)  ·  University of Oxford (47)  ·  Medicines for Malaria Venture (37)  ·  U.S. Army Medical Research and Development Command (22)  ·  Sanaria Inc. (20)  ·  GlaxoSmithKline (12)  ·  London School of Hygiene and Tropical Medicine (5)  ·  Novartis Pharmaceuticals (5)  ·  Radboud University Medical Center (5)  ·  European Vaccine Initiative (4)  ·  Pfizer (3)  ·  Swiss Tropical & Public Health Institute (3)  ·  University of Mississippi, Oxford (3)  ·  sigma-tau i.f.r. S.p.A. (3)  ·  BioNTech SE (2)

Countries

United States (77)  ·  United Kingdom (50)  ·  Mali (21)  ·  Australia (19)  ·  Burkina Faso (11)  ·  Netherlands (11)  ·  Tanzania (10)  ·  Kenya (7)  ·  Switzerland (7)  ·  The Gambia (6)  ·  France (4)  ·  Gabon (4)  ·  Germany (4)  ·  Thailand (4)  ·  Uganda (4)

Top investigators

Patrick E Duffy, M.D. (7)  ·  Adrian VS Hill, D.Phil, FRCP (5)  ·  James McCarthy, Prof (5)  ·  Adrian V S Hill, MD (4)  ·  Ulrike Lorch, MD FRCA FFPM (4)  ·  Adrian V Hill, DPhill FRCP (3)  ·  Adrian VS Hill (3)  ·  Adrian VS Hill, MA, BM BCh, DPhil, DM (3)  ·  Isabelle Borghini Fuhrer, PhD (3)  ·  Salim Abdulla, MD, PhD (3)  ·  Sara A Healy, M.D. (3)

Results publications

PMID 39787798, PMID 40245769, PMID 41014333, PMID 23526949, PMID 23899517, PMID 25211344, PMID 26292027, PMID 26292257, PMID 27695088, PMID 29389671, PMID 31932368, PMID 32239164, PMID 32275867, PMID 33717176, PMID 34194041, PMID 39324693, PMID 39708824, PMID 39805302, PMID 41176969, PMID 10190913, PMID 10501745, PMID 12663340, PMID 12742586, PMID 1313024, PMID 15069048, PMID 16904798, PMID 17075340, PMID 17428147, PMID 17940609, PMID 18213374, PMID 18231580, PMID 18253503, PMID 18270560, PMID 18378716, PMID 18545693, PMID 18612426, PMID 18698359, PMID 18930565, PMID 19093004, PMID 19390585, PMID 19569965, PMID 19673614, PMID 20107498, PMID 20140214, PMID 21058417, PMID 21352601, PMID 21410944, PMID 21745716, PMID 21752262, PMID 21799809

NIH funding

2019 (3), 2015 (2), 2016 (2), U01CI000211 (2), 2014 (1), 2018 (1), 5UM1AI148684-04 (1), N01AI085346 (1), R01AI025136 (1), R01HL086488 (1), R01NS074409 (1), U01AI065683 (1), U19AI065683 (1)